Phase i clinical trial of smad7 knockdown using antisense oligonucleotide in patients with active crohn's disease

Molecular Therapy

Volumn 20, Issue 4, 2012, Pages 870-876

  Monteleone, Giovanni ^a   Fantini, Massimo C ^a   Onali, Sara ^a   Zorzi, Francesca ^a   Sancesario, Giulia ^a   Bernardini, Sergio ^a   Calabrese, Emma ^a   Viti, Francesca ^b   Monteleone, Ivan ^a   Biancone, Livia ^a   Pallone, Francesco ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b GIULIANI S P A   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; GED 0301; SMAD7 PROTEIN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ARTICLE; BILIRUBIN BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERTENSION; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MALE; MORNING DOSAGE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; POTASSIUM BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; RELAPSE; RHINITIS; SIDE EFFECT; SIGNAL TRANSDUCTION; T WAVE INVERSION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; URINARY TRACT INFECTION; VOMITING;

MUS;

EID: 84859439270     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2011.290     Document Type: Article

References (24)

1. Kaser, A, Zeissig, S and Blumberg, RS (2010). Inflammatory bowel disease. Annu Rev Immunol 28: 573-621.
2. Mowat, C, Cole, A, Windsor, A, Ahmad, T, Arnott, I, Driscoll, R et al.; IBD Section of the British Society of Gastroenterology. (2011). Guidelines for the management of inflammatory bowel disease in adults. Gut 60: 571-607.
3. Burger, D and Travis, S (2011). Conventional medical management of inflammatory bowel disease. Gastroenterology 140: 1827-1837, e2.
4. Colombel, JF, Sandborn, WJ, Reinisch, W, Mantzaris, GJ, Kornbluth, A, Rachmilewitz, D et al.; SONIC Study Group. (2010). Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 362: 1383-1395.
5. Peyrin-Biroulet, L, Deltenre, P, de Suray, N, Branche, J, Sandborn, WJ and Colombel, JF (2008). Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 6: 644-653. (Pubitemid 351783447)
6. Smith, MA, Irving, PM, Marinaki, AM and Sanderson, JD (2010). Review article: malignancy on thiopurine treatment with special reference to inflammatory bowel disease. Aliment Pharmacol Ther 32: 119-130.
7. Ben-Horin, S and Chowers, Y (2011). Review article: loss of response to anti-TNF treatments in Crohn's disease. Aliment Pharmacol Ther 33: 987-995.
8. Xavier, RJ and Podolsky, DK (2007). Unravelling the pathogenesis of inflammatory bowel disease. Nature 448: 427-434. (Pubitemid 47123518)
9. Macdonald, TT and Monteleone, G (2005). Immunity, inflammation, and allergy in the gut. Science 307: 1920-1925. (Pubitemid 40404695)
10. Maloy, KJ and Powrie, F (2011). Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 474: 298-306.
11. Monteleone, G, Kumberova, A, Croft, NM, McKenzie, C, Steer, HW and MacDonald, TT (2001). Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J Clin Invest 108: 601-609. (Pubitemid 32777740)
12. Monteleone, G, Boirivant, M, Pallone, F and MacDonald, TT (2008). TGF-beta1 and Smad7 in the regulation of IBD. Mucosal Immunol 1 Suppl 1: S50-S53.
13. Boirivant, M, Pallone, F, Di Giacinto, C, Fina, D, Monteleone, I, Marinaro, M et al. (2006). Inhibition of Smad7 with a specific antisense oligonucleotide facilitates TGFbeta1-mediated suppression of colitis. Gastroenterology 131: 1786-1798. (Pubitemid 44958514)
14. Papadakis, KA, Prehn, J, Moreno, ST, Cheng, L, Kouroumalis, EA, Deem, R et al. (2001). CCR9-positive lymphocytes and thymus-expressed chemokine distinguish small bowel from colonic Crohn's disease. Gastroenterology 121: 246-254. (Pubitemid 32729371)
15. Saruta, M, Yu, QT, Avanesyan, A, Fleshner, PR, Targan, SR and Papadakis, KA (2007). Phenotype and effector function of CC chemokine receptor 9-expressing lymphocytes in small intestinal Crohn's disease. J Immunol 178: 3293-3300. (Pubitemid 46333214)
16. MacDonald, TT and Monteleone, G (2001). IL-12 and Th1 immune responses in human Peyer's patches. Trends Immunol 22: 244-247. (Pubitemid 32667510)
17. Agace, WW (2008). T-cell recruitment to the intestinal mucosa. Trends Immunol 29: 514-522.
18. Mora, JR and von Andrian, UH (2006). T-cell homing specificity and plasticity: new concepts and future challenges. Trends Immunol 27: 235-243. (Pubitemid 44308124)
19. Kang, SG, Lim, HW, Andrisani, OM, Broxmeyer, HE and Kim, CH (2007). Vitamin A metabolites induce gut-homing FoxP3+ regulatory T cells. J Immunol 179: 3724-3733.
20. Su, C, Lichtenstein, GR, Krok, K, Brensinger, CM and Lewis, JD (2004). A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease. Gastroenterology 126: 1257-1269. (Pubitemid 38552790)
21. Renna, S, Cammà, C, Modesto, I, Cabibbo, G, Scimeca, D, Civitavecchia, G et al. (2008). Meta-analysis of the placebo rates of clinical relapse and severe endoscopic recurrence in postoperative Crohn's disease. Gastroenterology 135: 1500-1509.
22. Hawinkels, LJ and Ten Dijke, P (2011). Exploring anti-TGF-ß therapies in cancer and fibrosis. Growth Factors 29: 140-152.
23. Santibañez, JF, Quintanilla, M and Bernabeu, C (2011). TGF-ß/TGF-ß receptor system and its role in physiological and pathological conditions. Clin Sci 121: 233-251.
24. Best, WR, Becktel, JM, Singleton, JW and Kern, F Jr (1976). Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 70: 439-444.